|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...28293031323334353637383940» |
- Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
New P3 trial: ARRIVE- EU: Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (clinicaltrials.gov) - Jan 10, 2012
P3, N=30, Terminated, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- | Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects (clinicaltrials.gov) - Jan 10, 2012
P1, N=19, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed
- Enrollment change: VDSS: Vitamin D Supplementation in Psychiatric Illnesses (clinicaltrials.gov) - Jan 9, 2012
P=N/A, N=12, Completed, Sponsor: University of Massachusetts, Worcester
Recruiting --> Completed N=10 --> 12
- ||| paliperidone extended release / Generic mfg.
Enrollment change: Power: Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants (clinicaltrials.gov) - Jan 9, 2012
P4, N=289, Completed, Sponsor: Janssen Korea, Ltd., Korea
N=10 --> 12 N=234 --> 289
- ||||||| Trial completion: yuyu: Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD (clinicaltrials.gov) - Jan 9, 2012
P3, N=144, Completed, Sponsor: Yuyu Pharma, Inc.
N=234 --> 289 Recruiting --> Completed
- |||| paliperidone extended release / Generic mfg.
Trial completion: Power: Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants (clinicaltrials.gov) - Jan 9, 2012
P4, N=289, Completed, Sponsor: Janssen Korea, Ltd., Korea
Recruiting --> Completed Active, not recruiting --> Completed
- |||| paliperidone extended release / Generic mfg.
Trial completion: PASS: Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants (clinicaltrials.gov) - Jan 9, 2012
P4, N=388, Completed, Sponsor: Janssen Korea, Ltd., Korea
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| New P3 trial: Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder) (clinicaltrials.gov) - Jan 8, 2012
P3, N=144, Recruiting, Sponsor: Yuyu Pharma, Inc.
- Enrollment open: Social Cognition Training in Schizophrenia (clinicaltrials.gov) - Jan 3, 2012
P=N/A, N=25, Recruiting, Sponsor: Oslo University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- acetylcysteine solution / Generic mfg.
New P1 trial: Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia (clinicaltrials.gov) - Jan 2, 2012
P1, N=13, Completed, Sponsor: Centre Hospitalier Universitaire Vaudois
- ||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Trial completion: Safety and Efficacy of Cariprazine in Patients With Schizophrenia (clinicaltrials.gov) - Jan 2, 2012
P3, N=617, Completed, Sponsor: Forest Laboratories
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial withdrawal: Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics (clinicaltrials.gov) - Dec 29, 2011
P=N/A, N=0, Withdrawn, Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting --> Completed Completed --> Withdrawn
- Enrollment change: Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics (clinicaltrials.gov) - Dec 29, 2011
P=N/A, N=0, Withdrawn, Sponsor: National Institute on Drug Abuse (NIDA)
Completed --> Withdrawn N=30 --> 0
- | New P2 trial, HEOR: PULSAR: Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia (clinicaltrials.gov) - Dec 29, 2011
P2, N=70, Recruiting, Sponsor: Medical Universtity of Lodz
- Enrollment change: SCHIZOCAN: Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse (clinicaltrials.gov) - Dec 27, 2011
P=N/A, N=97, Active, not recruiting, Sponsor: Assistance Publique - H
N=30 --> 0 N=330 --> 97
- Enrollment closed: SCHIZOCAN: Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse (clinicaltrials.gov) - Dec 27, 2011
P=N/A, N=97, Active, not recruiting, Sponsor: Assistance Publique - H
N=330 --> 97 Recruiting --> Active, not recruiting
- | New P2 trial: Cognitive Behavioral Therapy for Patients With an Early Psychosis (clinicaltrials.gov) - Dec 26, 2011
P2, N=60, Active, not recruiting, Sponsor: Oslo University Hospital
- ||||| Caplyta (lumateperone) - Intra / Cellular Therapies
New P2 trial: Study of a Novel Antipsychotic ITI-007 in Schizophrenia (clinicaltrials.gov) - Dec 22, 2011
P2, N=335, Completed, Sponsor: Intra-Cellular Therapies, Inc.
- risperidone / Generic mfg., paliperidone extended release / Generic mfg.
Trial completion: Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia (clinicaltrials.gov) - Dec 21, 2011
P4, N=58, Completed, Sponsor: Chonnam National University Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Trial initiation date: The Topical Niacin Skin Flush Test in First Episode Psychosis (clinicaltrials.gov) - Dec 19, 2011
P3, N=200, Recruiting, Sponsor: Capital District Health Authority, Canada
Recruiting --> Completed Initiation date: Sep 2011 --> Dec 2011
- | pregabalin / Generic mfg.
New P4 trial: PACS: Pregablin for Anxiety-comorbidity in Patients With Schizophrenia (clinicaltrials.gov) - Dec 19, 2011
P4, N=70, Recruiting, Sponsor: University of Aarhus
- | Enrollment open: The Topical Niacin Skin Flush Test in First Episode Psychosis (clinicaltrials.gov) - Dec 19, 2011
P3, N=200, Recruiting, Sponsor: Capital District Health Authority, Canada
Initiation date: Sep 2011 --> Dec 2011 Not yet recruiting --> Recruiting
- ||| Trial completion: RECONNECT-S: A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=600, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Detecting Risk of Suicide in a Pediatric Emergency Department (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=600, Completed, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Completed Recruiting --> Completed
- | iloperidone / Generic mfg.
New P1 trial: Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients (clinicaltrials.gov) - Dec 15, 2011
P1, N=29, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Trial completion: Safety and Efficacy of Cariprazine in Schizophrenia (clinicaltrials.gov) - Dec 15, 2011
P3, N=459, Completed, Sponsor: Forest Laboratories
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
New P1 trial: A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia (clinicaltrials.gov) - Dec 14, 2011
P1, N=88, Completed, Sponsor: Alkermes
- atomoxetine / Generic mfg.
Enrollment change: The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype (clinicaltrials.gov) - Dec 13, 2011
P2, N=11, Terminated, Sponsor: National Institute of Mental Health (NIMH)
Active, not recruiting --> Completed N=180 --> 11
- New P1 trial: FASY: A Community-health Worker Delivered HIV/STI Prevention Intervention for Internally Displaced Women in Leogane, Haiti (clinicaltrials.gov) - Dec 13, 2011
P1, N=200, Completed, Sponsor: Women's College Hospital
- || quetiapine / Generic mfg.
Enrollment change: UPTAQE: Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=387, Completed, Sponsor: AstraZeneca
N=180 --> 11 N=128 --> 387
- cannabidiol/delta-9-tetrahydrocannabivarin (GW42004) / Jazz
New P2 trial: Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine (clinicaltrials.gov) - Dec 12, 2011
P2, N=2, Terminated, Sponsor: GW Pharmaceuticals Ltd.
- risperidone / Generic mfg., desipramine / Generic mfg.
Trial initiation date: RADIAUS: Risperidone and Desipramine in Alcohol Use and Schizophrenia (clinicaltrials.gov) - Dec 8, 2011
P2, N=40, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
N=128 --> 387 Initiation date: Aug 2011 --> Dec 2011
- ||||| brilaroxazine (RP5063) / Reviva
New P2 trial: RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Dec 8, 2011
P2, N=228, Completed, Sponsor: Reviva Pharmaceuticals
- risperidone / Generic mfg., desipramine / Generic mfg.
Enrollment open: RADIAUS: Risperidone and Desipramine in Alcohol Use and Schizophrenia (clinicaltrials.gov) - Dec 8, 2011
P2, N=40, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Initiation date: Aug 2011 --> Dec 2011 Not yet recruiting --> Recruiting
- |||| Risperdal Consta (risperidone depot formulation) / J&J
Trial completion: An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Dec 8, 2011
P4, N=75, Completed, Sponsor: Janssen Korea, Ltd., Korea
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| bradanicline (ATA-101) / CODA Biotherap
New P2 trial: Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia (clinicaltrials.gov) - Dec 6, 2011
P2, N=603, Completed, Sponsor: Targacept Inc.
- HEOR: Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders (clinicaltrials.gov) - Dec 5, 2011
P=N/A, N=400, Enrolling by invitation, Sponsor: Department of Veterans Affairs
- || pomaglumetad methionil (DB103) / Denovo
New P3 trial: A Long-Term Study in Schizophrenia (clinicaltrials.gov) - Dec 5, 2011
P3, N=282, Terminated, Sponsor: Eli Lilly and Company
- Trial initiation date: Antipsychotic Discontinuation in Alzheimer's Disease (clinicaltrials.gov) - Dec 1, 2011
P4, N=180, Completed, Sponsor: New York State Psychiatric Institute
Active, not recruiting --> Completed Initiation date: Jan 2004 --> Aug 2004
- |||||||||| lurasidone / Generic mfg.
New P3 trial: Lurasidone Extended Use Study (clinicaltrials.gov) - Dec 1, 2011
P3, N=162, Completed, Sponsor: Sunovion
- ||| paliperidone extended release / Generic mfg.
Enrollment change: A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia (clinicaltrials.gov) - Nov 30, 2011
P4, N=84, Completed, Sponsor: Janssen-Cilag Turkey
Initiation date: Jan 2004 --> Aug 2004 N=122 --> 84
- |||| paliperidone extended release / Generic mfg.
Trial completion: A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia (clinicaltrials.gov) - Nov 30, 2011
P4, N=84, Completed, Sponsor: Janssen-Cilag Turkey
N=122 --> 84 Recruiting --> Completed
- Enrollment open: The Assessment of Movement Disorders Utilizing Live Two-Way Video (clinicaltrials.gov) - Nov 22, 2011
P=N/A, N=40, Recruiting, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Trial completion: An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia (clinicaltrials.gov) - Nov 22, 2011
P4, N=1809, Completed, Sponsor: Janssen-Cilag, S.A.
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Enrollment change: Impact of Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness (clinicaltrials.gov) - Nov 21, 2011
P3, N=13, Completed, Sponsor: University of British Columbia
Not yet recruiting --> Completed N=120 --> 13
- Trial completion: Impact of Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness (clinicaltrials.gov) - Nov 21, 2011
P3, N=13, Completed, Sponsor: University of British Columbia
N=120 --> 13 Recruiting --> Completed
- | GSK239512 / GSK
Enrollment change: Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia (clinicaltrials.gov) - Nov 17, 2011
P2, N=50, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=80 --> 50
- Enrollment open: Reducing Internalized Stigma in People With Serious Mental Illness (clinicaltrials.gov) - Nov 17, 2011
P2, N=276, Recruiting, Sponsor: Department of Veterans Affairs
N=80 --> 50 Not yet recruiting --> Recruiting
- | GSK239512 / GSK
Trial completion: Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia (clinicaltrials.gov) - Nov 17, 2011
P2, N=50, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness. (clinicaltrials.gov) - Nov 17, 2011
P=N/A, N=238, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Active, not recruiting --> Completed